By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Boehringer Ingelheim Corporation 

P.O. Box 368
900 Ridgebury Road
Ridgefield  Connecticut  06877-0368  U.S.A.
Phone: 203-798-99-88 Fax: 203-791-62-34


SEARCH JOBS








Company News
Real-World Data From Boehringer Ingelheim Show Lower Risk Of Stroke And Major Bleeding For Pradaxa (Dabigatran Etexilate Mesylate) Compared To Warfarin 2/24/2017 6:44:23 AM
Boehringer Ingelheim Release: FDA Expands Approval Of Tiotropium Respimat For Maintenance Treatment Of Asthma In Children 2/16/2017 9:22:51 AM
Boehringer Ingelheim Release: FDA Expands Approval Of SPIRIVA RESPIMAT (Tiotropium Bromide) Inhalation Spray For Maintenance Treatment Of Asthma In Children 2/16/2017 6:36:21 AM
Boehringer Ingelheim And Weill Cornell Medicine Announce New Collaboration To Discover Next Generation COPD Treatments 2/15/2017 6:40:51 AM
Sanofi (SNY) Unloads Five OTC Drugs to Ipsen (IPN.PA) for $88 Million to Pave Way for Boehringer Ingelheim Deal 2/13/2017 5:55:35 AM
Boehringer Ingelheim Release: Afatinib To Be Evaluated In Combination With PD-1 Inhibitor Pembrolizumab In New Trial For Patients With Squamous Cell Carcinoma Of The Lung 2/9/2017 8:36:01 AM
Boehringer Ingelheim Release: Afatinib To Be Evaluated In Combination With PD-1 Inhibitor Pembrolizumab In New Trial For Patients With Squamous Cell Carcinoma Of The Lung 2/9/2017 8:00:44 AM
BioMed X And Boehringer Ingelheim Launch New Crowdsourcing Project To Identify Key Regulatory Mechanisms In Innate Immunity 2/6/2017 8:13:55 AM
Boehringer Ingelheim Release: Jardiance (Empagliflozin) Becomes First Type 2 Diabetes Medicine In The EU To Include Cardiovascular Death Reduction Data In Label 1/26/2017 8:13:46 AM
Inovalon Release: Company Announces Agreement With Boehringer Ingelheim To Support Outcome-Based Contracting 1/23/2017 6:46:43 AM
12345678910...
//-->